Video Interview: Adherium mHealth Device Helps Pharma Boost Patient Compliance
This article was originally published in Clinica
Garth Sutherland, CEO of Adherium Ltd, tells Mike Ward, global director of content of Informa's pharma insights portfolio, about Adherium's endeavor in the digital health space. Sutherland outlines how the B2B digital health company, listed in Australia last year, is selling its Smartinhaler technology to big pharma, hospitals and disease management companies. The platform itself is made up of a cloud-based server that harbors data collected by Adherium's Smartinhaler, a medical device that records drug usage and can be clipped onto any prescribed inhaler used to treat asthma and COPD. Not only can the patient view the data collected on their smart phone or tablet, it can also be accessed by the patient's medical providers. Moreover, along with the data collection, the device provides patients with audio and visual reminders to take their medication.
You may also be interested in...
With nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company's Smartinhaler to improve outcomes for children with poorly controlled asthma should boost the pairing of digital technologies with drugs.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.